Concise Communication

Evaluation of a hybrid antimicrobial restriction process at a large academic medical center

Jesse D. Smith PharmD candidate 20211, Linh H. Nguyen PharmD candidate 20211, Tamara Krekel PharmD, BCP, BCIDP2, Jerrica Waggoner PharmD, BCP, BCCP3, David J. Ritchie PharmD, BCP, BCIDP2,4, Michael J. Durkin MD MPH5, Kevin Hsueh MD5 and Elizabeth A. Neuner PharmD, BCPS, BCIDP

1University of Health Sciences and Pharmacy in St. Louis, St. Louis, Missouri, 2Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, Missouri, 3Center for Clinical Excellence, BJC Healthcare, St. Louis, Missouri, 4Pharmacy Practice Department, University of Health Sciences and Pharmacy in St. Louis, St. Louis, Missouri and 5Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri

Abstract

We conducted a retrospective review of a hybrid antimicrobial restriction process demonstrating adherence to appropriate use criteria in 72% of provisional-only orders, in 100% of provisional orders followed by ID orders, and in 97% of ID-initiated orders. Therapy interruptions occurred in 24% of provisional orders followed by ID orders.

(Received 6 May 2021; accepted 3 August 2021)

Preauthorization is a foundational intervention for antimicrobial stewardship programs. Preauthorization improves initial adherence to guidelines, decreases Clostridiodes difficile infections (CDIs), and reduces antimicrobial use and costs.1,2 However, a strict preauthorization policy places a heavy workload on the authorizing providers (particularly after hours), contributes to a perceived loss of prescriber autonomy, and may contribute to antibiotic administration delays.3,4

In September 2019, the Barnes-Jewish Hospital Antimicrobial Stewardship Program (BJH-ASP) transitioned from strict preauthorization to a hybrid restriction system to improve patient safety and reduce the risk of missed orders and delays in therapy. For select restricted antimicrobials, a provisional order set was created that allowed up to a 24-hour supply to be utilized without any preauthorization. Additionally, the order set contained an optional order for an infectious diseases (ID) consultation if therapy beyond 24 hours was desired. Orders for restricted antimicrobials with a duration longer than 24 hours were limited to ID prescribers only and a separate order was required for provisional orders to continue beyond 24 hours. All provisional orders are reviewed by the ASP within 24 hours via real-time notifications when orders are placed. In this study, we sought to track and describe process measures related to restricted antimicrobial orders.

Author for correspondence: Elizabeth A. Neuner, Barnes-Jewish Hospital, One Barnes-Jewish Hospital Plaza, Mailstop 90-52-411, St Louis, Missouri 63110. E-mail: elizabeth.neuner@bjc.org

PREVIOUS PRESENTATION. These data were presented in abstract form at the American Society of Health-System Pharmacists Midyear Clinical Meeting, held virtually in December 2020.


© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
intravenous acyclovir (n = 23, 53%) for provisional-only orders and (n = 21, 62%) provisional followed by ID orders compared to ceftolozane/tazobactam (n = 18, 47%) for ID-initiated orders. Adherence to appropriate use criteria was 72% in provisional-only orders, 100% for provisional followed by ID orders, and 97% for ID-initiated orders. ID consultations were ordered for 11 (26%) provisional-only orders, 100% for provisional followed by ID orders, and 97% for ID initiated orders. Review of the provisional-only orders revealed that 1 patient was not adherent to appropriate use criteria due to aminoglycoside toxicity.

Among the 34 provisional orders followed by ID orders, 8 patients (24%) experienced an interruption in therapy at the point of transition between the provisional and ID-initiated order: 5 patients experienced an interruption in therapy for intravenous acyclovir, 1 patient for meropenem/vaborbactam, 1 patient for ceftazidime/avibactam, and 1 patient for ceftolozane/tazobactam. The median time for the delayed administration of an ID-initiated order was 252 minutes (range, 111–650). Review of medications for 34 provisional orders revealed that 5 patients experienced an interruption in therapy for intravenous acyclovir, 1 patient for meropenem/vaborbactam, 1 patient for ceftazidime/avibactam, and 1 patient for ceftolozane/tazobactam.

Table 1. Appropriate Use Criteria for Restricted Antimicrobials

<table>
<thead>
<tr>
<th>Antimicrobial</th>
<th>Institution Appropriate Use Criteria*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acyclovir, IV</td>
<td>• Viral meningitis/encephalitis</td>
</tr>
<tr>
<td></td>
<td>• Disseminated herpes simplex virus (HSV)/Varicella zoster virus (VZV) infection</td>
</tr>
<tr>
<td></td>
<td>• HSV/VZV infection in patients unable to take enteral acyclovir</td>
</tr>
<tr>
<td>Ampicillin/sulbactamb</td>
<td>• <em>Acinetobacter baumannii</em> infections</td>
</tr>
<tr>
<td>Ceftazidime/avibactam</td>
<td>• Definitive treatment of infections caused by <em>Klebsiella pneumoniae</em> carbapenemase (KPC)–producing or OXA-48–producing <em>Enterobacteriaceae</em> when other susceptible therapies are not suitable based on efficacy and/or safety concerns</td>
</tr>
<tr>
<td></td>
<td>• Definitive treatment of infections caused by multidrug-resistant (MDR) <em>Pseudomonas</em> if the organism is susceptible to ceftazidime/avibactam and resistant to cefepime, ceftazidime, ceftolozane/tazobactam, imipenem, meropenem and piperacillin/tazobactam, when other susceptible therapies are not based on efficacy and/or safety concerns.</td>
</tr>
<tr>
<td>Ceftolozane/tazobactam</td>
<td>• Definitive treatment of infections caused by MDR <em>Pseudomonas</em> if the organism is susceptible to ceftolozane/tazobactam and resistant to cefepime, ceftazidime, imipenem, meropenem and piperacillin/tazobactam, when other susceptible therapies are not suitable based on efficacy and/or safety concerns.</td>
</tr>
<tr>
<td>Fidaxomicin</td>
<td>• Definitive treatment of recurrent <em>Clostridioides difficile</em> infection (CDI)</td>
</tr>
<tr>
<td></td>
<td>• Definitive treatment of an initial CDI in patients at high risk for recurrence (age ≥ 65 years plus severe disease or receiving concomitant antibiotics)</td>
</tr>
<tr>
<td>Meropenem/vaborbactam</td>
<td>• Definitive treatment of a KPC-producing <em>Enterobacteriaceae</em> resistant to ceftazidime/avibactam but susceptible to meropenem/vaborbactam</td>
</tr>
<tr>
<td></td>
<td>• Alternative to ceftazidime/avibactam combination therapy, meropenem/vaborbactam can be considered for combined coverage of KPC-producing <em>Enterobacteriaceae</em> AND meropenem/vaborbactam-susceptible gram-positive organism</td>
</tr>
</tbody>
</table>

*Indications outside of the appropriate use criteria will be allowed on a case-by-case basis after discussion with the Barnes-Jewish Hospital Antimicrobial Stewardship Program.*

*bAppropriate use criteria during times of national shortage.*
of the interruptions in therapy cases identified documented reasons for 2 cases: 1 loss of intravenous access and 1 held for procedure.

**Discussion**

Our restriction process, which hybridizes a provisional unrestricted system with standard preauthorization, maintained high adherence (88% overall) to institutional appropriate use criteria. Use of the restricted antimicrobials (~14 orders per month) remained stable during the study period, and we observed no evidence of teams “gaming” the provisional unrestricted process to obtain additional doses of restricted agents. These results suggest that the hybrid process did not lead to unnecessary initiation of restricted antimicrobials. Our results are comparable to previous data suggesting that preauthorization improves appropriateness of restricted antimicrobials. Dassner et al. evaluated the effect of a second-sign process for restricted antimicrobials and found appropriate use was 84.5% by general practitioners and 92.9% for ID-approved orders. These findings are comparable to the rates of adherence to appropriate use criteria in our study: 72% provisional-only orders, 100% provisional followed by ID orders, and 97% for ID-initiated orders.

Athans et al. describe an approach to antimicrobial restriction based on antimicrobial stewardship goals of improving patient outcomes and safety while reducing resistance and costs. The BJH-ASP selected agents requiring preauthorization based on similar principles but also included antimicrobials affected by shortages. A survey of members of the Emerging Infections Network in 2016 reported that 70% of ID physicians were affected by antimicrobial shortages in the previous 2 years and that ASPs were highly involved in the management. Placing durations of therapy restrictions on antimicrobials experiencing shortages was a mechanism by which the ASP could monitor usage in real time. This intervention was effective for acyclovir, with 83% adherence to use criteria among provisional-only orders and 100% adherence for provisional followed by ID orders. For ampicillin/sublactam, only 46% of provisional-only orders were adherent. This discrepancy was primarily the result of ampicillin/sublactam use for surgical prophylaxis, not an approved indication during the shortage.

Interruptions in therapy occurred in the provisional followed by ID orders; after removal of cases with documented reasons, interruptions in therapy occurred in 18% of cases. Data suggest that delays in the first dose of effective antimicrobial therapy can cause significant patient harm; however, the impact of subsequent delays or interruptions in therapy is much less clear. Additionally, the best way to define an interruption in therapy is uncertain, although they appear to be common. Leisman et al. evaluated delays from first- to second-dose antibiotics in sepsis cases using a definition of delay of ≥25% of the recommended dosing interval, and 33% of patients experienced a major delay. Even though any delay in therapy is undesirable, in this hybrid system, delays were not observed with the first dose of antimicrobial and were comparable and no worse than reports in the literature. Further work is needed to identify reasons for delays and how to prevent their occurrence. Our initial investigation did not identify trends in hours, days of the week, or primary service.

Our study has several limitations. The sample size was small, and the study was conducted at a single center. We used a retrospective design, and the study lacked a comparator arm. There is no standard definition for interruption in therapy, and while the definition in our study was based on Institute for Safe Medication Practices guidance, it was also conservative.

In conclusion, a hybrid antimicrobial restriction system demonstrated high adherence to appropriate use criteria, including short-term criteria introduced as a part of antimicrobial shortage management processes. Further work is needed to evaluate the significance of therapy interruptions and to prevent interruptions in therapy due to preauthorization processes.

**Acknowledgments.** We thank Caleb McLeod, PharmD, and Nicholas Pauley, PharmD, for assistance on the project proposal. We acknowledge Jennifer Bushwitz, PharmD, and Ed Casabar, PharmD, for their work in designing and implementing the preauthorization process.

**Financial support.** M.J.D. received salary support from National Institutes of Health (grant no. K23DE029514).

**Conflicts of interest.** T.K. reports being on the speakers’ bureau for Merck, manufacturers of fidaxomicin. D.R. reports honoraria from Merck and AbbVie. All other authors report no conflicts of interest relevant to this article.

**References**